Bristol-Myers Squibb Company (BMY)

pos +0.40
Today's Range: 70.94 - 71.88 | BMY Avg Daily Volume: 5,967,800
Last Update: 05/31/16 - 3:59 PM EDT
Volume: 7,162,253
YTD Performance: 3.66%
Open: $71.36
Previous Close: $71.31
52 Week Range: $51.82 - $73.06
Oustanding Shares: 1,669,307,273
Market Cap: 119,038,301,638
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 6 6 6
Moderate Buy 1 1 1 1
Hold 7 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 2 2 1 0
Mean Rec. 2.32 2.37 2.18 1.96
Latest Dividend: 0.38
Latest Dividend Yield: 2.13%
Dividend Ex-Date: 03/30/16
Price Earnings Ratio: 35.48
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
35.48 76.50 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
14.55% 4.25% 50.44%
Revenue 4.30 -0.10 -0.02
Net Income -19.60 -0.30 -0.13
EPS -22.30 -0.20 -0.07
Earnings for BMY:
Revenue 16.56B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.65 $0.64 $2.60 $3.35
Number of Analysts 7 5 10 9
High Estimate $0.68 $0.69 $2.71 $3.68
Low Estimate $0.64 $0.61 $2.50 $3.01
Prior Year $0.53 $0.39 $2.01 $2.60
Growth Rate (Year over Year) 23.45% 64.10% 29.35% 28.97%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
May 05, 2016 | 6:52 AM EDT
Shares of BMY now seen reaching $75, according to Jefferies. Estimates also increased, givne a faster expected ramp for the Opdivo mono...
May 03, 2016 | 7:04 AM EDT
BMY - Bristol-Myers Squibb Co Annual Shareholders Meeting - 10AM
It's mighty tough to put a multiple on a declining business.
The drug maker is approaching overbought territory, but is set up well for more upside.
We recently got a golden cross of the 50-day and 200-day averages.
Apr 07, 2016 | 7:47 AM EDT
Coverage of BMY was started with a Sell rating, Societe Generale said. $48 price target. Estimates also below consensus, given lower ex...
The pharmaceutical company's stock is likely to weaken further if it declines below $61 and $60 in the days ahead.
The group rallied yesterday, but it's still not out of the woods.

Columnist Conversations

The Fed has been talkative lately about the 'strength' in the economy with a 2% rate of growth. Certainly tha...
Market flat as we hit the noon hour. Oil tries once again to scale the $50 level. Biotech goes for three wee...
I would think he sees the boatload of cash coming to AGN if/when they close the TEVA deal for their generics. ...
Looking like a slightly up start to the holiday shortened trading week as consumer spending posts its best gai...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.